Literature DB >> 7718636

HDL subfractions as altered in cancer patients.

C Anchisi1, B Batetta, F Sanna, A M Fadda, A M Maccioni, S Dessi.   

Abstract

Previous studies from the authors' laboratories have shown that cancer patients are characterized by lower levels of high-density lipoprotein cholesterol (HDL-C) compared with those of normal subjects. HDLs are a complex class of lipoproteins which can be divided mainly into two categories, HDL2 and HDL3, that have not only different lipid and protein composition but also different functions. Therefore, for a better understanding of the metabolism of HDL during tumour growth, the different subfractions of HDL (HDL2 and HDL3) were analysed in the serum of neoplastic patients using a rapid and simple high-performance liquid chromatography (HPLC) method for the analysis. The results obtained showed that serum from neoplastic patients exhibits a peculiar pattern in the distribution of HDL subfractions, consisting of a sharp decrease in HDL3 and a consequent increase of the normal HDL2/HDL3 ratio. It is suggested that evaluation of the HDL subfractions may be of clinical relevance for cancer status and that due to its simplicity, short analytical time and small sample volume required, the HPLC technique used in this study can be easily applied to routine analysis in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718636     DOI: 10.1016/0731-7085(94)e0026-w

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  A lipoprotein source of cholesteryl esters is essential for proliferation of CEM-CCRF lymphoblastic cell line.

Authors:  Sabrina Uda; Simonetta Accossu; Stefano Spolitu; Maria Collu; Fabrizio Angius; Francesca Sanna; Sebastiano Banni; Claudia Vacca; Elisabetta Murru; Claudia Mulas; Giacomo Diaz; Barbara Batetta
Journal:  Tumour Biol       Date:  2011-12-10

2.  Cholesterol esters as growth regulators of lymphocytic leukaemia cells.

Authors:  M F Mulas; C Abete; D Pulisci; A Pani; B Massidda; S Dessì; A Mandas
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

3.  Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma.

Authors:  Yang Lv; Li-Yun Miao; Qiu-Fang Chen; Yan Li; Zhi-Xiang Shi; Xuan-Sheng Ding
Journal:  Onco Targets Ther       Date:  2016-01-22       Impact factor: 4.147

4.  High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts.

Authors:  Fabrizio Angius; Stefano Spolitu; Sabrina Uda; Stefania Deligia; Alessandra Frau; Sebastiano Banni; Maria Collu; Simonetta Accossu; Clelia Madeddu; Roberto Serpe; Barbara Batetta
Journal:  Sci Rep       Date:  2015-12-07       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.